Marta Casarrubios

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

Mariano Provencio, Ernest Nadal, Amelia Insa et al. · The Lancet Oncology · 2020 · 828 citations

Medicine, Oncology, Pharmacology +14

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)

Mariano Provencio, Roberto Serna‐Blasco, Ernest Nadal et al. · Journal of Clinical Oncology · 2022 · 335 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy

Marta Casarrubios, Alberto Cruz‐Bermúdez, Ernest Nadal et al. · Clinical Cancer Research · 2021 · 67 citations · Full text

Life Sciences, Immunology, Oncology +17

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

Marta Casarrubios, Mariano Provencio, Ernest Nadal et al. · Journal for ImmunoTherapy of Cancer · 2022 · 62 citations · Full text

Medicine, Immunology, Oncology +17

Pancreatic cancer–restricted cryptic antigens are targets for T cell recognition

Zackery A. Ely, Zachary Kulstad, Gürcan Günaydın et al. · Science · 2025 · 60 citations

Life Sciences, Immunology, Oncology +17